Format

Send to

Choose Destination
BMC Med. 2017 Apr 6;15(1):75. doi: 10.1186/s12916-017-0840-6.

Emerging concepts in liquid biopsies.

Author information

1
Institute of Human Genetics, Medical University of Graz, Harrachgasse 21/8, A-8010, Graz, Austria.
2
Institute of Human Genetics, Medical University of Graz, Harrachgasse 21/8, A-8010, Graz, Austria. michael.speicher@medunigraz.at.
3
BioTechMed, Graz, Austria. michael.speicher@medunigraz.at.

Abstract

Characterizing and monitoring tumor genomes with blood samples could achieve significant improvements in precision medicine. As tumors shed parts of themselves into the circulation, analyses of circulating tumor cells, circulating tumor DNA, and tumor-derived exosomes, often referred to as "liquid biopsies", may enable tumor genome characterization by minimally invasive means. Indeed, multiple studies have described how molecular information about parent tumors can be extracted from these components. Here, we briefly summarize current technologies and then elaborate on emerging novel concepts that may further propel the field. We address normal and detectable mutation levels in the context of our current knowledge regarding the gradual accumulation of mutations during aging and in light of technological limitations. Finally, we discuss whether liquid biopsies are ready to be used in routine clinical practice.

KEYWORDS:

Cell-free DNA; Circulating tumor DNA; Circulating tumor cells; Disease monitoring; Liquid biopsy; Precision medicine

PMID:
28381299
PMCID:
PMC5382440
DOI:
10.1186/s12916-017-0840-6
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center